Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Crohns Disease (Regional Enteritis)-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Crohns Disease (Regional Enteritis)-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Crohns Disease (Regional Enteritis)-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Crohns Disease (Regional Enteritis)-Pipeline Review, H2 2016



Executive Summary

Crohn's Disease (Regional Enteritis)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Crohn's Disease (Regional Enteritis)-Pipeline Review, H2 2016', provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)

The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects

The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Crohn's Disease (Regional Enteritis) Overview 8

Therapeutics Development 9

Crohn's Disease (Regional Enteritis)-Therapeutics under Development by Companies 11

Crohn's Disease (Regional Enteritis)-Therapeutics under Investigation by Universities/Institutes 19

Crohn's Disease (Regional Enteritis)-Pipeline Products Glance 20

Crohn's Disease (Regional Enteritis)-Products under Development by Companies 24

Crohn's Disease (Regional Enteritis)-Products under Investigation by Universities/Institutes 33

Crohn's Disease (Regional Enteritis)-Companies Involved in Therapeutics Development 34

Crohn's Disease (Regional Enteritis)-Therapeutics Assessment 113

Drug Profiles 136

Crohn's Disease (Regional Enteritis)-Dormant Projects 400

Crohn's Disease (Regional Enteritis)-Discontinued Products 412

Crohn's Disease (Regional Enteritis)-Product Development Milestones 414

Appendix 426

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016 24

Number of Products under Development for Crohn's Disease (Regional Enteritis)-Comparative Analysis, H2 2016 25

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Development by Companies, H2 2016 (Contd..6) 33

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Development, H2 2016 37

Comparative Analysis by Unknown Stage Development, H2 2016 38

Products under Development by Companies, H2 2016 39

Products under Development by Companies, H2 2016 (Contd..1) 40

Products under Development by Companies, H2 2016 (Contd..2) 41

Products under Development by Companies, H2 2016 (Contd..3) 42

Products under Development by Companies, H2 2016 (Contd..4) 43

Products under Development by Companies, H2 2016 (Contd..5) 44

Products under Development by Companies, H2 2016 (Contd..6) 45

Products under Development by Companies, H2 2016 (Contd..7) 46

Products under Development by Companies, H2 2016 (Contd..8) 47

Products under Investigation by Universities/Institutes, H2 2016 48

Crohn's Disease (Regional Enteritis)-Pipeline by 4D Pharma Plc, H2 2016 49

Crohn's Disease (Regional Enteritis)-Pipeline by 4SC AG, H2 2016 50

Crohn's Disease (Regional Enteritis)-Pipeline by AB Science SA, H2 2016 51

Crohn's Disease (Regional Enteritis)-Pipeline by AbbVie Inc, H2 2016 52

Crohn's Disease (Regional Enteritis)-Pipeline by Alfa Wassermann S.p.A, H2 2016 53

Crohn's Disease (Regional Enteritis)-Pipeline by Alteogen Inc., H2 2016 54

Crohn's Disease (Regional Enteritis)-Pipeline by Amgen Inc., H2 2016 55

Crohn's Disease (Regional Enteritis)-Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 56

Crohn's Disease (Regional Enteritis)-Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 57

Crohn's Disease (Regional Enteritis)-Pipeline by Arena Pharmaceuticals, Inc., H2 2016 58

Crohn's Disease (Regional Enteritis)-Pipeline by Astellas Pharma Inc., H2 2016 59

Crohn's Disease (Regional Enteritis)-Pipeline by BioLingus AG, H2 2016 60

Crohn's Disease (Regional Enteritis)-Pipeline by Bionovis SA, H2 2016 61

Crohn's Disease (Regional Enteritis)-Pipeline by BioTherapeutics Inc., H2 2016 62

Crohn's Disease (Regional Enteritis)-Pipeline by Calypso Biotech SA, H2 2016 63

Crohn's Disease (Regional Enteritis)-Pipeline by Celgene Corporation, H2 2016 64

Crohn's Disease (Regional Enteritis)-Pipeline by ChemoCentryx, Inc., H2 2016 65

Crohn's Disease (Regional Enteritis)-Pipeline by ChironWells GmbH, H2 2016 66

Crohn's Disease (Regional Enteritis)-Pipeline by CLL Pharma, H2 2016 67

Crohn's Disease (Regional Enteritis)-Pipeline by Coherus BioSciences, Inc., H2 2016 68

Crohn's Disease (Regional Enteritis)-Pipeline by Commence Bio, Inc., H2 2016 69

Crohn's Disease (Regional Enteritis)-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 70

Crohn's Disease (Regional Enteritis)-Pipeline by DBV Technologies S.A., H2 2016 71

Crohn's Disease (Regional Enteritis)-Pipeline by Eisai Co., Ltd., H2 2016 72

Crohn's Disease (Regional Enteritis)-Pipeline by Eli Lilly and Company, H2 2016 73

Crohn's Disease (Regional Enteritis)-Pipeline by Enterome Bioscience SA, H2 2016 74

Crohn's Disease (Regional Enteritis)-Pipeline by Enzo Biochem, Inc., H2 2016 75

Crohn's Disease (Regional Enteritis)-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 76

Crohn's Disease (Regional Enteritis)-Pipeline by Ferring International Center S.A., H2 2016 77

Crohn's Disease (Regional Enteritis)-Pipeline by Galapagos NV, H2 2016 78

Crohn's Disease (Regional Enteritis)-Pipeline by Genentech, Inc., H2 2016 79

Crohn's Disease (Regional Enteritis)-Pipeline by Genor BioPharma Co., Ltd., H2 2016 80

Crohn's Disease (Regional Enteritis)-Pipeline by Gilead Sciences, Inc., H2 2016 81

Crohn's Disease (Regional Enteritis)-Pipeline by iCo Therapeutics Inc., H2 2016 82

Crohn's Disease (Regional Enteritis)-Pipeline by Idera Pharmaceuticals, Inc., H2 2016 83

Crohn's Disease (Regional Enteritis)-Pipeline by Immune Response BioPharma, Inc., H2 2016 84

Crohn's Disease (Regional Enteritis)-Pipeline by Innovent Biologics, Inc., H2 2016 85

Crohn's Disease (Regional Enteritis)-Pipeline by Johnson & Johnson, H2 2016 86

Crohn's Disease (Regional Enteritis)-Pipeline by Jyant Technologies, Inc., H2 2016 87

Crohn's Disease (Regional Enteritis)-Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 88

Crohn's Disease (Regional Enteritis)-Pipeline by KPI Therapeutics, Inc., H2 2016 89

Crohn's Disease (Regional Enteritis)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 90

Crohn's Disease (Regional Enteritis)-Pipeline by MedImmune, LLC, H2 2016 91

Crohn's Disease (Regional Enteritis)-Pipeline by Merck & Co., Inc., H2 2016 92

Crohn's Disease (Regional Enteritis)-Pipeline by Mesoblast Limited, H2 2016 93

Crohn's Disease (Regional Enteritis)-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 94

Crohn's Disease (Regional Enteritis)-Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 95

Crohn's Disease (Regional Enteritis)-Pipeline by Mycenax Biotech Inc., H2 2016 96

Crohn's Disease (Regional Enteritis)-Pipeline by Neovacs SA, H2 2016 97

Crohn's Disease (Regional Enteritis)-Pipeline by Oncobiologics, Inc., H2 2016 98

Crohn's Disease (Regional Enteritis)-Pipeline by Oncodesign SA, H2 2016 99

Crohn's Disease (Regional Enteritis)-Pipeline by OSE Immunotherapeutics, H2 2016 100

Crohn's Disease (Regional Enteritis)-Pipeline by Pfenex Inc., H2 2016 101

Crohn's Disease (Regional Enteritis)-Pipeline by Pfizer Inc., H2 2016 102

Crohn's Disease (Regional Enteritis)-Pipeline by Pieris Pharmaceuticals, Inc., H2 2016 103

Crohn's Disease (Regional Enteritis)-Pipeline by Pluristem Therapeutics Inc., H2 2016 104

Crohn's Disease (Regional Enteritis)-Pipeline by Protalix BioTherapeutics, Inc., H2 2016 105

Crohn's Disease (Regional Enteritis)-Pipeline by Qu Biologics Inc., H2 2016 106

Crohn's Disease (Regional Enteritis)-Pipeline by Re-Pharm Limited, H2 2016 107

Crohn's Disease (Regional Enteritis)-Pipeline by RedHill Biopharma Ltd., H2 2016 108

Crohn's Disease (Regional Enteritis)-Pipeline by Sandoz International GmbH, H2 2016 109

Crohn's Disease (Regional Enteritis)-Pipeline by SATT North SAS, H2 2016 110

Crohn's Disease (Regional Enteritis)-Pipeline by Second Genome, Inc., H2 2016 111

Crohn's Disease (Regional Enteritis)-Pipeline by Selexys Pharmaceuticals Corporation, H2 2016 112

Crohn's Disease (Regional Enteritis)-Pipeline by Selvita S.A., H2 2016 113

Crohn's Disease (Regional Enteritis)-Pipeline by Shire Plc, H2 2016 114

Crohn's Disease (Regional Enteritis)-Pipeline by Sigmoid Pharma Limited, H2 2016 115

Crohn's Disease (Regional Enteritis)-Pipeline by Soligenix, Inc., H2 2016 116

Crohn's Disease (Regional Enteritis)-Pipeline by Stelic Institute & Co., Inc., H2 2016 117

Crohn's Disease (Regional Enteritis)-Pipeline by Sylentis S.A.U., H2 2016 118

Crohn's Disease (Regional Enteritis)-Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016 119

Crohn's Disease (Regional Enteritis)-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 120

Crohn's Disease (Regional Enteritis)-Pipeline by Therapeutic Proteins International, LLC, H2 2016 121

Crohn's Disease (Regional Enteritis)-Pipeline by Tiziana Life Sciences Plc, H2 2016 122

Crohn's Disease (Regional Enteritis)-Pipeline by Trino Therapeutics Limited, H2 2016 123

Crohn's Disease (Regional Enteritis)-Pipeline by TxCell SA, H2 2016 124

Crohn's Disease (Regional Enteritis)-Pipeline by Ventria Bioscience, H2 2016 125

Crohn's Disease (Regional Enteritis)-Pipeline by Virobay Inc., H2 2016 126

Crohn's Disease (Regional Enteritis)-Pipeline by Xbrane Biopharma AB, H2 2016 127

Assessment by Monotherapy Products, H2 2016 128

Assessment by Combination Products, H2 2016 129

Number of Products by Stage and Target, H2 2016 131

Number of Products by Stage and Mechanism of Action, H2 2016 139

Number of Products by Stage and Route of Administration, H2 2016 148

Number of Products by Stage and Molecule Type, H2 2016 150

Crohn's Disease (Regional Enteritis)-Dormant Projects, H2 2016 415

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..1), H2 2016 416

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..2), H2 2016 417

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..3), H2 2016 418

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..4), H2 2016 419

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..5), H2 2016 420

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..6), H2 2016 421

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..7), H2 2016 422

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..8), H2 2016 423

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..9), H2 2016 424

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..10), H2 2016 425

Crohn's Disease (Regional Enteritis)-Dormant Projects (Contd..11), H2 2016 426

Crohn's Disease (Regional Enteritis)-Discontinued Products, H2 2016 427

Crohn's Disease (Regional Enteritis)-Discontinued Products (Contd..1), H2 2016 428

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016 24

Number of Products under Development for Crohn's Disease (Regional Enteritis)-Comparative Analysis, H2 2016 25

Number of Products under Development by Companies, H2 2016 26

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Products, H2 2016 37

Assessment by Monotherapy Products, H2 2016 128

Assessment by Combination Products, H2 2016 129

Number of Products by Top 10 Targets, H2 2016 130

Number of Products by Stage and Top 10 Targets, H2 2016 130

Number of Products by Top 10 Mechanism of Actions, H2 2016 138

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 138

Number of Products by Top 10 Routes of Administration, H2 2016 147

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 147

Number of Products by Top 10 Molecule Types, H2 2016 149

Number of Products by Stage and Top 10 Molecule Types, H2 2016 149

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4D Pharma Plc

4SC AG

AB Science SA

AbbVie Inc

Alfa Wassermann S.p.A

Alteogen Inc.

Amgen Inc.

Ampio Pharmaceuticals, Inc.

ARA Healthcare Pvt. Ltd.

Arena Pharmaceuticals, Inc.

Astellas Pharma Inc.

BioLingus AG

Bionovis SA

BioTherapeutics Inc.

Calypso Biotech SA

Celgene Corporation

ChemoCentryx, Inc.

ChironWells GmbH

CLL Pharma

Coherus BioSciences, Inc.

Commence Bio, Inc.

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

Eisai Co., Ltd.

Eli Lilly and Company

Enterome Bioscience SA

Enzo Biochem, Inc.

Epirus Biopharmaceuticals, Inc.

Ferring International Center S.A.

Galapagos NV

Genentech, Inc.

Genor BioPharma Co., Ltd.

Gilead Sciences, Inc.

iCo Therapeutics Inc.

Idera Pharmaceuticals, Inc.

Immune Response BioPharma, Inc.

Innovent Biologics, Inc.

Johnson & Johnson

Jyant Technologies, Inc.

Kang Stem Biotech Co., Ltd.

KPI Therapeutics, Inc.

Kyorin Pharmaceutical Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Neovacs SA

Oncobiologics, Inc.

Oncodesign SA

OSE Immunotherapeutics

Pfenex Inc.

Pfizer Inc.

Pieris Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

Protalix BioTherapeutics, Inc.

Qu Biologics Inc.

Re-Pharm Limited

RedHill Biopharma Ltd.

Sandoz International GmbH

SATT North SAS

Second Genome, Inc.

Selexys Pharmaceuticals Corporation

Selvita S.A.

Shire Plc

Sigmoid Pharma Limited

Soligenix, Inc.

Stelic Institute & Co., Inc.

Sylentis S.A.U.

TaiwanJ Pharmaceuticals Co., Ltd.

Takeda Pharmaceutical Company Limited

Therapeutic Proteins International, LLC

Tiziana Life Sciences Plc

Trino Therapeutics Limited

TxCell SA

Ventria Bioscience

Virobay Inc.

Xbrane Biopharma AB

Crohn's Disease (Regional Enteritis) Therapeutic Products under Development, Key Players in Crohn's Disease (Regional Enteritis) Therapeutics, Crohn's Disease (Regional Enteritis) Pipeline Overview, Crohn's Disease (Regional Enteritis) Pipeline, Crohn's Disease (Regional Enteritis) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand